Type of security: Stock
Sector: Health Care
Industry: Biotechnology: Biological Products (No Diagnostic Substances)
Market Capitalization: 408.34 M
The data is delayed by 15 minutes.
AGEN is in the long-term down -64% below S&P in 7 years.
Description: Agenus Inc., a biopharmaceutical company, is developing a portfolio of immuno-oncology candidates, including checkpoint modulators (CPMs), heat shock protein vaccines, and adjuvants. Its proprietary discovery engine Retrocyte Display is designed to generate therapeutic antibody drug candidates incorporating full-length IgG format human antibody libraries expressed in mammalian B-lineage cells. The company?s portfolio of checkpoint modulator programs is advancing in preclinical development. Its heat shock protein vaccines for cancer and infectious disease are in Phase II studies. The company?s QS-21 Stimulon adjuvant platform, which is partnered with GlaxoSmithKline and Janssen, includes various candidates in Phase III trials. In addition, it has 23 programs are in clinical development. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||86.88 M||EPS||-1.28||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||28.59%||Sales Growth - Q/Q||144.16%||P/E||-2.7|
|P/E To EPS Growth||P/S||40||P/BV||8.83||Price/Cash Per Share|
|Price/Free Cash Flow||-9.95||ROA||-51.88%||ROE||-131.58%||ROI|
|Current Ratio||4.06||Quick Ratio||4.05||Long Term Debt/Equity||Debt Ratio||0.45|
|Gross Margin||Operating Margin||-507.29%||Net Profit Margin||-596.23%||Dividend Payout Ratio|
|Cash From Financing Activities||36.1 M||Cash From Investing Activities||14.21 M||Cash From Operating Activities||3.3 M||Gross Profit|
|Net Profit||-40.41 M||Operating Profit||-33.2 M||Total Assets||117.32 M||Total Current Assets||85.15 M|
|Total Current Liabilities||21 M||Total Debt||11.5 M||Total Liabilities||71.07 M||Total Revenue||6.38 M|
|High 52 week||6.04||Low 52 week||1.59||Last close||2.66||Last change||0%|
|RSI||32.39||Average true range||0.12||Beta||1.14||Volume||925.23 K|
|Simple moving average 20 days||-2.22%||Simple moving average 50 days||-6.96%||Simple moving average 200 days||-17.66%|
|Performance Week||4.72%||Performance Month||-6.99%||Performance Quart||-21.53%||Performance Half||60.24%|
|Performance Year||-35.12%||Performance Year-to-date||11.76%||Volatility daily||2.12%||Volatility weekly||4.75%|
|Volatility monthly||9.73%||Volatility yearly||33.72%||Relative Volume||223.31%||Average Volume||1.27 M|
|New High||New Low|
2020-06-02 11:30:03 | Has Agenus AGEN Outpaced Other Medical Stocks This Year?
2020-06-02 08:30:00 | FDA Clears IND for iNKT Cells to Treat COVID-19 Patients
2020-06-01 09:21:01 | Is the Options Market Predicting a Spike in Agenus AGEN Stock?
2020-05-29 13:28:00 | Here's Why Agenus Rose as Much as 23.3% Today
2020-05-29 09:43:01 | Protalix Submits BLA for Fabry Disease Candidate PRX-102
2020-05-29 08:00:00 | ASCO Presentation of Agenus' AGEN1181 by Dr. Steven O'Day
2020-05-28 09:42:01 | Mersana Stock Spikes on Interim Data on Cancer Candidate
2020-05-28 09:10:01 | Ironwood to Halt MD-7246 Development After Study Failure
2020-05-14 11:56:03 | Agenus' AGEN IND for iNKT Therapy Gets FDA Acceptance
2020-05-14 08:00:00 | Agenus NextGen CTLA-4 Antibody AGEN1181 Data to be Presented at ASCO
2020-05-13 09:54:00 | FDA Clears AgenTus IND for Allogeneic iNKT Cell Therapy
2020-05-13 09:43:01 | Agenus AGEN: Strong Industry, Solid Earnings Estimate Revisions
2020-05-11 12:00:04 | Agenus AGEN Upgraded to Buy: Here's Why
2020-05-08 19:30:38 | Agenus Inc AGEN Q1 2020 Earnings Call Transcript
2020-05-08 01:11:05 | Edited Transcript of AGEN earnings conference call or presentation 7-May-20 12:30pm GMT
2020-05-07 09:35:01 | Agenus AGEN Reports Q1 Loss, Tops Revenue Estimates
2020-05-07 08:29:11 | Recap: Agenus Q1 Earnings
2020-05-07 08:00:00 | Agenus First Quarter Results and Update
2020-04-30 12:34:04 | Analysts Estimate Agenus AGEN to Report a Decline in Earnings: What to Look Out for
2020-04-16 08:56:12 | Agenus' Shares March Higher, Can It Continue?
2020-04-16 08:38:12 | Are Options Traders Betting on a Big Move in Agenus AGEN Stock?
2020-04-07 13:04:00 | Agenus Receives Fast Track Designation for Balstilimab in Advanced Cervical Cancer
2020-04-06 09:00:01 | Why Agenus AGEN Stock Might be a Great Pick
2020-03-24 12:00:04 | Agenus AGEN Moves to Buy: Rationale Behind the Upgrade
2020-03-19 16:05:39 | Edited Transcript of AGEN earnings conference call or presentation 12-Mar-20 12:30pm GMT
2020-03-13 11:57:03 | Agenus AGEN Q4 Earnings Beat Estimates, Revenues Rise Y/Y
2020-03-12 10:05:02 | Agenus AGEN Reports Q4 Loss, Tops Revenue Estimates
2020-03-10 09:14:00 | First QS-21 Royalty Payment Due to Agenus is Triggered
2020-03-05 12:30:05 | Earnings Preview: Agenus AGEN Q4 Earnings Expected to Decline
2020-02-28 08:58:01 | Immunomedics IMMU Reports Wider-Than-Expected Q4 Loss
2020-02-27 09:10:02 | Global Blood GBT Q4 Earnings Miss, Voxelotor Gets FDA Nod
2020-02-27 09:07:02 | Horizon Therapeutics' HZNP Q4 Earnings Beat Estimates
2020-02-21 12:00:05 | Agenus AGEN Upgraded to Strong Buy: What Does It Mean for the Stock?
2020-02-06 15:12:00 | Agenus Announces Investor Day on February 20, 2020
2020-01-17 05:12:25 | Did You Manage To Avoid Agenus's NASDAQ:AGEN 22% Share Price Drop?
2020-01-09 09:48:02 | Agenus Initiates Phase I Study on Oncology Candidate AGEN1223
2020-01-08 10:04:03 | Amicus FOLD Provides Updates on AT-GAA for Pompe Disease
2020-01-08 08:30:00 | Agenus Commences Phase 1 trial with AGEN1223
2020-01-03 10:54:03 | Innate Pharma's Filing for Leukemia Drug Accepted in Europe
2020-01-03 09:55:02 | Pulmatrix Surges on License Agreement With Johnson & Johnson
2020-01-03 09:41:02 | Amicus Progresses on Pipeline Development Amid Competition
2020-01-03 09:01:02 | Arena ARNA Expands Strategic Deal With Beacon Discovery